



Reply to “The statistical significance may be misinterpreted”

Yu-Wen Cheng^{a,b}, Yang-Yi Chen^c, Chien-Ju Lin^d, Yi-Ting Chen^{e,f}, Ann-Shung Lieu^{g,h}, Hung-Pei Tsai^g, Aij-Lie Kwan^{g,h,i,*}

^aDepartment of Neurosurgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC; ^bGraduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC; ^cDepartment of Dermatology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC; ^dSchool of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC; ^eDepartment of Pathology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC; ^fDepartment of Pathology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC; ^gDivision of Neurosurgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, ROC; ^hDepartment of Surgery, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC; ⁱDepartment of Neurosurgery, University of Virginia, Charlottesville, VA, USA

DEAR EDITOR,

We would like to thank Li et al¹ for their interest in our work.² In their Letter to the Editor, they summarized our most important findings and raised a possible concern to our work. Reply below is our responses for their concerns.

From traditional the aspect of pathology, the histopathological stage is the currently widely used for analysis, but we hope to create a newly classification to predict the prognosis of glioblastoma. Because the pathological stage is subjective, there still consist of bias for the prognosis. If we classify from the gene expression, the amount of the expression will be objective and provide more corrective prediction. From the database of website and the result of our research, NLRP12 is the poor prognosis marker,^{3,4} thus we analysis high and low expression of this gene through Cox regression model will be property as a target to predict the survival of glioblastoma patients.

We would like to thank Li et al again and hope that our responses could be of help.

REFERENCES

1. Li YT, Chang WH. The statistical significance may be misinterpreted. *J Chin Med Assoc* 2023;86:534.
2. Cheng YW, Chen YY, Lin CJ, Chen YT, Lieu AS, Tsai HP, et al. High expression of NLRP12 predicts poor prognosis in patients with intracranial glioma. *J Chin Med Assoc* 2023;86:88–97.
3. Sharma N, Saxena S, Agrawal I, Singh S, Srinivasan V, Arvind S, et al. Differential expression profile of NLRs and AIM2 in glioma and implications for NLRP12 in glioblastoma. *Sci Rep* 2019; 9:8480.
4. Lin Q, Wu L, Ma Z, Chowdhury FA, Mazumder HH, Du W. Persistent DNA damage-induced NLRP12 improves hematopoietic stem cell function. *JCI Insight* 2020;5:e133365.

* Address correspondence. Dr. Aij-Lie Kwan, Division of Neurosurgery, Department of Surgery, Kaohsiung Medical University, Hospital, Kaohsiung Medical University, 100, Tzyou 1st Road, Kaohsiung 807, Taiwan, ROC. E-mail address: aijliekwan@yahoo.com.tw (A.-L. Kwan).

Conflicts of interest: The authors declare that they have no conflicts of interest related to the subject matter or materials discussed in this article.

Journal of Chinese Medical Association. (2023) 86: 535.

Received February 13, 2023; accepted February 16, 2023.

doi: 10.1097/JCMA.0000000000000908.

Copyright © 2023, the Chinese Medical Association. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)